With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
|Videos|June 23, 2020
Contagion Live News Network: Pneumococcal Conjugate Vaccine V114
Author(s)Contagion® Editorial Staff
An overview of today's top infectious disease stories.
Advertisement
Investigational PCV Meets Safety and Immunogenicity Objectives in Initial Phase 3 Studies
Merck has announced results from 2 initial Phase 3 studies, PNEU-FLU and PNEU-WAY, evaluating the firm’s 15-valent pneumococcal conjugate vaccine (PCV).
V114 uses pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein, including serotypes 22F and 33F. These serotypes are widely associated with invasive pneumococcal disease globally and are not found in the currently licensed pneumococcal conjugate vaccine for adults.
“Certain populations are at greater risk for pneumococcal disease, reinforcing the importance of investigating new interventions focused on their specific needs,” said Luwy Musey, MD, executive director in biologics, vaccine clinical research, at Merck Research Laboratories. “Results from these first two Phase 3 studies of V114 are encouraging and we look forward to sharing additional data in the future from our ongoing clinical development program, including our pivotal studies assessing the immunogenicity of V114 and its potential to protect against the serotypes most likely to cause invasive disease.” Read
CONTAGION LIVE NEWS NETWORK - JUNE 23, 2020:
(Assistant Editor Grant Gallagher gives an overview of the day's top stories.)
Advertisement
Related to this article
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
Advertisement
Advertisement